Harmony Biosciences
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| neurology | ×1.01 | 3 |
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 5 disclosed transactions, Harmony Biosciences concentrates its licensing activity in Neurology, RareDisease. Harmony Biosciences pays a 1.01x premium over market median, with the strongest premiums in Neurology (1.01x). Their most common deal structure is Acquisition, with an average disclosed value of $345M. Most recent activity: 2025.
Premium by therapeutic area
How Harmony Biosciences pays relative to peer medians in each TA
Pipeline coverage & gaps
Harmony Biosciences has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| AcquisitionPrimary | 2 | $48M | $440M |
| LicensePrimary | 2 | $26M | $406M |
| Collaboration | 1 | $15M | $35M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | CBS105 (treatment-resistant narcolepsy) and CBS104 (refractory epilepsy) cell-replacement therapy programs | CiRC Biosciences | treatment-resistant narcolepsy | discovery | $15M | $35M |
| 2024 | EPX-100 (clemizole) | Epygenix Therapeutics | Dravet syndrome | phase_2 | $35M | $680M |
| 2024 | Pitolisant / WAKIX | Bioprojet | narcolepsy | approved | $26M | $419M |
| 2024 | TPM-1116 | Bioprojet | narcolepsy | phase_1 | $26M | $393M |
| 2023 | Zygel | Zynerba Pharmaceuticals | Fragile X syndrome | phase_3 | $60M | $200M |
How this is computed
For each Harmony Biosciences deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 1.006, clamped to [0.7, 1.5].